Randomized, double-blind, placebo controlled, parallel-group, prospective clinical study to analyse the effect of evolocumab on vascular function.
Status: Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Oct 2018
Price : $35 *
At a glance
- Drugs Evolocumab (Primary)
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- 11 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Nov 2018.
- 17 Aug 2018 New trial record